Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 51 articles: HTML format Text format

Single Articles

January 2010
1. LAM ET , Au JL, Otterson GA, Guillaume Wientjes M, et al
   Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. KWON JH , Kim JH, Lee JA, Shin HC, et al
   Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. YANAGIHARA K , Yoshimura K, Niimi M, Yasuda H, et al
   Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
4. AKASAKA K , Kaburagi T, Yasuda S, Ohmori K, et al
   Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. NOGUEIRA A , Catarino R, Coelho A, Araujo A, et al
   Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. DREDGE K , Kink JA, Johnson RM, Bytheway I, et al
   The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.
   Cancer Chemother Pharmacol. 2009;65:191-5.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
7. JIANG L , Wang DY, Zhu ZH, Tang LF, et al
   Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. CHOI YJ , Rho JK, Jeon BS, Choi SJ, et al
   Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. YAMAMOTO N , Tamura T, Yamamoto N, Yamada K, et al
   Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
   Cancer Chemother Pharmacol. 2009;64:1165-72.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. ISRAYELYAN A , Shannon EJ, Baghian A, Kearney MT, et al
    Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn.
    Cancer Chemother Pharmacol. 2009;64:1201-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
11. YAMAGUCHI M , Takeo S, Suemitsu R, Matsuzawa H, et al
    Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. HORIO Y , Osada H, Shimizu J, Ogawa S, et al
    Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
13. ZHOU HJ , Zhang JL, Li A, Wang Z, et al
    Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
14. ORTEGA J , Hayes JM, Antonia S
    Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. WONG MK , Lo AI, Lam B, Lam WK, et al
    Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. SHIRAO K , Yoshino T, Boku N, Kato K, et al
    A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Cancer Chemother Pharmacol. 2009;64:557-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
17. WANG X , Zhao G, Van S, Jiang N, et al
    Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. KIM HJ , Lee NS, Lee SC, Bae SB, et al
    A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
    Cancer Chemother Pharmacol. 2009;64:371-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. GONG Y , Ren L, Zhou L, Zhu J, et al
    Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Cancer Chemother Pharmacol. 2009;64:327-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. LEE KH , Kim MK, Kim YH, Ryoo BY, et al
    Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
    Cancer Chemother Pharmacol. 2009;64:317-25.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. SUN N , Sun X, Chen B, Cheng H, et al
    MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
22. ROBERT F , Harper K, Ackerman J, Gupta S, et al
    A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naive patients with stage IIIB or stage IV non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. WATERS SH , Gillibrand A, Berry H, Kumar S, et al
    Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. CASSILETH BR , Rizvi N, Deng G, Yeung KS, et al
    Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
25. YAMAMOTO N , Tamura T, Kurata T, Yamamoto N, et al
    A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. TOTANI Y , Saito Y, Hayashi M, Tada T, et al
    A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. FORNARO L , Masi G, Bursi S, Loupakis F, et al
    A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
    Cancer Chemother Pharmacol. 2009;63:965-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
28. ZHOU ZT , Xu XH, Wei Q, Lu MQ, et al
    Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. KANO Y , Tanaka M, Akutsu M, Mori K, et al
    Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. STORDAL B , Davey R
    ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
    Cancer Chemother Pharmacol. 2009;63:661-72.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
31. CHANG MH , Kim KH, Jun HJ, Kim HS, et al
    Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
32. RUBIO JC , Vazquez S, Vazquez F, Amenedo M, et al
    A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. ROBEY RW , Obrzut T, Shukla S, Polgar O, et al
    Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. LING YH , Li T, Perez-Soler R, Haigentz M Jr, et al
    Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. AZUMA K , Sasada T, Kawahara A, Hattori S, et al
    Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
36. GUAN J , Lo M, Dockery P, Mahon S, et al
    The x (c) (-) cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. SCHMID P , Krocker J, Kreienberg R, Klare P, et al
    Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. LEE GW , Kang MH, Kim HG, Kang JH, et al
    Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. LIU X , Chan SY, Ho PC
    Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
    Cancer Chemother Pharmacol. 2008;63:167-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. KELNER MJ , McMorris TC, Rojas RJ, Estes LA, et al
    Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Cancer Chemother Pharmacol. 2008;63:19-26.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. THAM LS , Wang LZ, Soo RA, Lee HS, et al
    Does saturable formation of gemcitabine triphosphate occur in patients?
    Cancer Chemother Pharmacol. 2008;63:55-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
42. EPSTEIN RJ , Leung TW
    Tumor resensitization to erlotinib following brief substitution of cetuximab.
    Cancer Chemother Pharmacol. 2008;62:1111-2.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
43. MORI K , Kobayashi H, Kamiyama Y, Kano Y, et al
    A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. BEG MS , Komrokji RS, Ahmed K, Safa MM, et al
    Oxaliplatin-induced immune mediated thrombocytopenia.
    Cancer Chemother Pharmacol. 2008;62:925-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
45. NAKAMURA M , Koizumi T, Hayasaka M, Yasuo M, et al
    Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. BIGIONI M , Benzo A, Irrissuto C, Lopez G, et al
    Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Cancer Chemother Pharmacol. 2008;62:621-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. ZERBE LK , Dwyer-Nield LD, Fritz JM, Redente EF, et al
    Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Cancer Chemother Pharmacol. 2008;62:605-20.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
48. LOIBL S , Murmann C, Schwedler K, Warm M, et al
    Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. OSAKO T , Ito Y, Ushijima M, Takahashi S, et al
    Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
50. KURODA H , Kawamura M, Hato T, Kamiya K, et al
    Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine.
    Cancer Chemother Pharmacol. 2008;62:331-3.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2007
51. FABI A , Metro G, Papaldo P, Mottolese M, et al
    Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: